Fig. 6: TRIM21 promotes ferroptosis by targeting METTL3 in vivo.

A Treatment scheme for subcutaneous tumor models. B Tumors were excised and photographed. C Differences in tumor volume in response to different treatments (n = 5). D Quantification of immunofluorescence tissue staining with anti-4-HNE antibody. E Hematoxylin and eosin (H&E) staining and immunofluorescence staining with anti 4-HNE antibody. Scale bar, 50 µm. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant).